help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zimniski, S. J.
Right arrow Articles by Vaitukaitis, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zimniski, S. J.
Right arrow Articles by Vaitukaitis, J. L.

Endocrinology, Vol 111, 625-634, Copyright © 1982 by Endocrine Society

ARTICLES

Fate of human chorionic gonadotropin bound to rat corpora lutea

SJ Zimniski, EA Rorke, MA Sickel and JL Vaitukaitis

The current studies were designed to ascertain the fate of hCG bound to rat corpora luteal cell receptors. Graded doses of highly purified hCG (CR119), ranging from 0.1-10.1 micrograms, were injected. Groups of pseudopregnant rats received iodinated hCG, unlabeled hCG, or both. Supraphysiological levels of hCG were used to enhance the internalization of hCG and its receptors. When ovarian membrane pellets (48,000 X g) were subjected to continuous sucrose density ultracentrifugation, two different ovarian membrane fractions (F1 and F2) bound hCG. Although an increase in hCG binding to the F2 membrane fraction was observed between 1-6 h after a single 0.1-microgram [125I]iodo-hCG injection, no subsequent enhanced binding to that fraction was observed. However, the F1 fraction bound at least 3 fold more hCG than did the F2 fraction 1, 6, 12, and 24 h after the injection of 0.1 micrograms [125I]iodo-hCG. When groups of animals were injected with 0.1, 1.0, or 10.0 micrograms unlabeled highly purified hCG, peak serum, ovarian plasma membrane, and ovarian intracellular hCG concentrations were observed at different times after hormone injection and suggested the progressive transfer of hCG from serum to ovarian fractions in a time- and dose-dependent relationship. Although no intracellular hCG was detected until 60 min after the single 0.1- microgram injection of hCG, both serum and membrane-bound levels were measurable within 15 min of that injection. From these observations, we suggest that ovarian intracellular hCG does not reflect significant contamination with serum or interstitial fluid or from significant dissociation of membrane-bound hCG during tissue handling. Finally, when intracellular hCG was subjected to continuous sucrose density gradient ultracentrifugation, a single major 135I peak was observed, and this comigrated with [125I]iodo-hCG. Our interpretation of the foregoing observations is that the major intracellular form of hCG is not receptor bound.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1982 by The Endocrine Society